Bone Resorption Inhibitor

Features

• Ready-to-use formulation
• Zoledronic acid injection is a bisphosphonate indicated for the treatment of: Hypercalcemia of malignancy, multiple myeloma and bone metastases from solid tumors
• The zoledronic acid injection infusion time must not be less than 15 minutes given over a constant infusion rate
• Zoledronic acid injection must not be mixed with calcium or other divalent cation-containing infusion solutions, such as Lactated Ringer's solution, and should be administered as a single intravenous solution in a line separate from all other drugs
• Infusion bottle with built-in plastic hanger
• One bottle with 100 mL solution contains 5.330 mg of zoledronic acid monohydrate, equivalent to 5 mg zoledronic acid on an anhydrous basis
• Inactive Ingredients: 4950 mg of mannitol, USP; and 30 mg of sodium citrate, USP